Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticles

References

• Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Röhl I, Leshchiner ES, Langer R, Anderson DG. (2009). Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther, 17, 872–879.
   PubMed Web of Science ®Google Scholar
• Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Röder N, Löffler K, Lange C, Fechtner M, Möpert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J. (2008). Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res, 68, 9788–9798.
   PubMed Web of Science ®Google Scholar
• Bouclier C, Moine L, Hillaireau H, Marsaud V, Connault E, Opolon P, Couvreur P, Fattal E, Renoir JM. (2008). Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha. Biomacromolecules, 9, 2881–2890.
   PubMed Web of Science ®Google Scholar
• Caracciolo G, Pozzi D, Caminiti R, Marchini C, Montani M, Amici A, Amenitsch H. (2008). Enhanced transfection efficiency of multicomponent lipoplexes in the regime of optimal membrane charge density. J Phys Chem B, 112, 11298–11304.
   PubMed Web of Science ®Google Scholar
• Davis ME. (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm, 6, 659–668.
   PubMed Web of Science ®Google Scholar
• Harms J, Wang X, Kim T, Yang X, Rathore AS. (2008). Defining process design space for biotech products: case study of Pichia pastoris fermentation. Biotechnol Prog, 24, 655–662.
   PubMed Web of Science ®Google Scholar
• Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME. (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA, 104, 5715–5721.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BY, Rutka JT, Chan WC. (2008). Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol, 3, 145–150.
   PubMed Web of Science ®Google Scholar
• Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest, 119, 661–673.
   PubMed Web of Science ®Google Scholar
• Kawano K, Onose E, Hattori Y, Maitani Y. (2009). Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone. Mol Pharm, 6, 98–104.
   PubMed Web of Science ®Google Scholar
• Kirdar AO, Green KD, Rathore AS. (2008). Application of multivariate data analysis for identification and successful resolution of a root cause for a bioprocessing application. Biotechnol Prog, 24, 720–726.
   PubMed Web of Science ®Google Scholar
• Kusumoto K. (2009). Structural features of glutamate-based lipidic materials for small interfering RNA delivery system. J Biomed Mater Res A, 89, 739–750.
   PubMedGoogle Scholar
• Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, Huang X, Hansen TM, Dande P, Wada C, Hubbard RD, Kohlbrenner WM, Fesik SW, Shen Y. (2011). A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA, 17, 603–612.
   PubMed Web of Science ®Google Scholar
• Mandenius CF, Graumann K, Schultz TW, Premstaller A, Olsson IM, Petiot E, Clemens C, Welin M. (2009). Quality-by-design for biotechnology-related pharmaceuticals. Biotechnol J, 4, 600–609.
   PubMedGoogle Scholar
• Rathore AS. (2009). Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol, 27, 546–553.
   PubMed Web of Science ®Google Scholar
• Rini BI, Selk LM, Vogelzang NJ. (1999). Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res, 5, 2766–2772.
   PubMed Web of Science ®Google Scholar
• Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. (2006). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther, 13, 1222–1234.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 28, 172–176.
   PubMed Web of Science ®Google Scholar
• Spagnou S, Miller AD, Keller M. (2004). Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry, 43, 13348–13356.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. (2001). Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res, 7, 2285–2291.
   PubMed Web of Science ®Google Scholar
• Wang L, Koynova R, Parikh H, MacDonald RC. (2006). Transfection activity of binary mixtures of cationic o-substituted phosphatidylcholine derivatives: the hydrophobic core strongly modulates physical properties and DNA delivery efficacy. Biophys J, 91, 3692–3706.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8, 129–138.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. (2006). RNAi-mediated gene silencing in non-human primates. Nature, 441, 111–114.
   PubMed Web of Science ®Google Scholar